Cypress Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$285K Buy
2,254
+75
+3% +$9.88K 0.08% 87
2026
Q1
$304K Buy
2,179
+12
+0.6% +$1.68K 0.09% 79
2025
Q4
$266K Buy
2,167
+60
+3% +$7.29K 0.07% 80
2025
Q3
$234K Sell
2,107
-107
-5% -$12.2K 0.07% 83
2025
Q2
$245K Buy
+2,214
New +$236K 0.07% 79
2024
Q3
Sell
-13
Closed -$892 184
2024
Q2
$892 Buy
+13
New +$868 ﹤0.01% 334
2022
Q1
Sell
-3,030
Closed -$220K 215
2021
Q4
$220K Sell
3,030
-180
-6% -$12.4K 0.03% 190
2021
Q3
$224K Buy
3,210
+3,207
+106,900% +$225K 0.03% 171
2021
Q2
$0 Hold
3
﹤0.01% 89
2021
Q1
$0 Buy
+3
New +$193 ﹤0.01% 113
2020
Q3
Sell
-22,595
Closed -$1.74M 65
2020
Q2
$1.74M Buy
+22,595
New +$1.73M 0.77% 16
2019
Q4
$1.38M Buy
21,191
+92
+0.4% +$5.99K 0.58% 24
2019
Q3
$1.34M Sell
21,099
-51
-0.2% -$3.33K 0.61% 21
2019
Q2
$1.43M Sell
21,150
-984
-4% -$64.7K 0.65% 23
2019
Q1
$1.44M Buy
22,134
+910
+4% +$60.5K 0.6% 26
2018
Q4
$1.33M Buy
+21,224
New +$1.48M 0.61% 28

Other funds holding GILD

Cypress Capital's GILD Position: Q2 2026 in Review

Cypress Capital increased its Gilead Sciences (GILD) stake by 3.4% in Q2 2026, buying an estimated $9.88K and bringing the position to 2,254 shares worth $285K. The position accounts for 0.08% of the portfolio, ranked #87.

Cypress Capital first reported a position in GILD in Q4 2018 and has held it in 16 quarters since. The position peaked at $1.74M in Q2 2020. 425 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cypress Capital held 2,254 shares of Gilead Sciences worth $285K as of Q2 2026.
  • Cypress Capital bought 75 Gilead Sciences shares in Q2 2026, an estimated $9.88K.
  • Gilead Sciences made up 0.08% of Cypress Capital's portfolio in Q2 2026, its #87 holding.
  • Cypress Capital first reported a position in Gilead Sciences in Q4 2018 and has held it in 16 quarters since.
  • Cypress Capital's Gilead Sciences position peaked at $1.74M in Q2 2020.
  • 425 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cypress Capital's 13F filing for Q2 2026, filed 17 Jul 2026.